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The secretion of ANF by the rat lung was demonstrated in the present study. Four forms of immunoreactive 
ANF were detected in rat lung homogenates, including the 126 amino acid prohormone but only a low 
molecular mass peptide was released during lung perfusion. The released ANF inhibited forskolin-stimulat- 
ed aldosterone secretion from rat zona glomerulosa cell suspensions, and this biological effect was compara- 
ble to that of the synthetic C-terminal part of the prohormone (Arg- 10 I-Tyr- 126). 
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1. INTRODUCTION 
Although recently discovered in mammalian car- 
diocytes, ANF [ 1,2] is not only a cardiac hormone. 
Its presence has been noted in various endocrine 
and neural rat tissues, such as different parts of the 
brain [3], the hypothalamus [4], the pituitary [5], 
ganglia of the autonomic nervous system [6] and 
the lungs [7,8]. In this investigation we provide 
direct evidence of the release of the biologically 
active form of ANF from isolated perfused rat 
lungs. 
2. MATERIALS AND METHODS 
Male Wistar rats (300 g) were anesthetized with 
an intraperitoneal injection of pentobarbital 
(1.6 mg/lOO g body wt), after which they were 
killed and their lungs perfused according to the 
technique of Engineer et al. [9]. In brief, the heart 
and lungs were totally removed and rapidly per- 
fused with oxygenated Krebs buffer via the pulmo- 
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nary artery. The lungs were perfused at an initial 
rate of 10 ml/min and inflated several times to 
eliminate all traces of blood. After the cannula in- 
side the pulmonary artery was tied, the heart was 
discarded. The lungs were again perfused, at a rate 
of 2 ml/min, and the trachea was clamped with the 
lungs inflated. Collection of the effluent was com- 
menced after a 5-min stabilization period. 
Three perfusates (30 ml each) were collected on 
ice during 15 min and immediately mixed with an 
equal volume of 0.1 M acetic acid containing the 
protease inhibitors to give a final concentration of 
1 mg/ml EDTA, lo-’ M PMSF (phenylmethylsul- 
fonyl fluoride), and 5 ,uM pepstatin-A. In another 
series of experiments, 2-ml aliquots of perfusate 
were collected separately every min on ice and mix- 
ed with an equal volume of 0.1 M acetic acid con- 
taining EDTA, PMSF and pepstatin-A in the same 
concentration mentioned above. Immunoreactive 
ANF (IR-ANF) in the perfusate was measured by 
specific radioimmunoassay (RIA) after extraction 
with Sep-Pak cartridges (Waters Associates, 
Milford, MA), as described [lo]. The recovery of 
[1125]ANF was 75-85%. 
Three other lung perfusates (30 ml each) ob- 
tained during a 15-min perfusion period were pool- 
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ed, and after Sep-Pak extraction and 
lyophilization, they were purified on a Cis PBon- 
dapak column, using an LKB system for reverse- 
phase HPLC (RP-HPLC). The samples were ap- 
plied to the HPLC column in 0.1% trifluoroacetic 
acid (TFA). Elution was performed with a linear 
gradient of 15-45% acetonitrile in 0.1% TFA. 
2-ml fractions were collected, and ANF was 
measured in 100~~1 ahquots (in duplicate) by direct 
RIA [ 111. Three fractions containing IR-ANF were 
lyophilized, and its biological activity was assessed 
by studying its effect on forskolin-stimulated 
aldosterone secretion in rat zona glomerulosa cell 
suspensions. After dissolving in medium, the 
amount of isolated ANF in the HPLC fractions of 
rat lung perfusates tested for biological activity 
was determined by RIA. 
In additional experiments, the lungs of 
decapitated and exsanguinated rats were washed in 
saline and homogenized in 5 ml of 0.1 M acetic 
acid with proteases inhibitors. The supernatant, 
extracted with Sep-Pak after centrifugation at 
20000 rpm, was purified by RP-HPLC under, the 
conditions described above. The ANF content was 
determined in all HPLC fractions by RIA [l 11. 
Zona glomerulosa cell suspensions of the 
adrenals were prepared as outlined elsewhere [121. 
After the adrenals were freed from pericapsular 
fat, decapsulation was accomplished by bisecting 
the gland and gently squeezing out the inner por- 
tion. The capsular tissue was incubated in Krebs- 
Ringer bicarbonate buffer (pH 7.4) with 0.2% 
glucose (KRGB), 4% bovine serum albumin, 
2 mg/ml collagenase and 0.2 mg/ml DNase in a 
water bath at 37°C with continuous shaking for 
two lo-min periods, followed by mechanical 
dispersion of the cells. After centrifugation and 
double washing with KRBG (4% BSA), the cells 
were re-suspended in KRBG containing 0.5% 
BSA, and passed through a nylon filter (pore size 
50 pm). The number and viability of cells were 
checked under a light microscope after staining 
with trypan blue solution. The suspensions con- 
tained 3 x lo5 cells in a volume of 1 ml incubation 
medium and, for each dilution of IR-ANF purified 
from rat lung perfusate, 4 replicates were done. 
Corresponding fractions of an HPLC ‘blank’ run 
were employed as controls. 1OOpM forskolin 
(Calbiochem, La Jolla, CA) was used for the 
stimulation of aldosterone secretion. The cells 
18 
were incubated at 37°C in water-saturated air con- 
taining 5% COZ. At the end of the incubation 
period (1 h), the cells were centrifuged and the 
supernatant frozen at - 20°C until radioim- 
munoassayed for aldosterone by a technique 
developed in our laboratory. Aldosterone was 
measured directly in the incubation medium 
without prior extraction, using antibody generous- 
ly provided by Dr P. Vecsei (Dept of Phar- 
macology, University of Heidelberg). The 200~1 
of medium diluted 1:4 (control) or 1: 10 (ex- 
perimental) were assayed in duplicates. 
The statistical significance of the difference be- 
tween forskolin-stimulated aldosterone (mean f 
SE) in the absence (control) or presence of various 
concentrations of IR-ANF isolated from rat lung 
perfusate or synthetic ANF (Arg-lOl-Tyr-126) 
was analysed by Student’s t-test for unpaired 
observations. For calculation of the rat lung IR- 
ANF molar concentration, a molecular mass of 
3063 Da for the 28 amino acid peptide ANF 
(Ser-99-Tyr- 126) was used. 
3. RESULTS 
Fig.1 (panel A) shows the RP-HPLC elution 
pattern of rat lung homogenates, which yielded 
four immunoreactive peaks. A similar pattern was 
observed when the homogenates were boiled for 
5 min in 0.1 M acetic acid containing trasylol 
(10000 units/ml) and leupeptin (1OOpM). RP- 
HPLC of rat lung perfusates (fig. 1, panel B) 
revealed the presence of one immunoreactive peak 
which had the same elution profile as synthetic 
ANF (Ser-99-Tyr-126). The immunoreactive peak 
which eluted at a higher acetonitrile concentration 
had the same elution pattern as the 126 amino acid 
prohormone ANF (Asn-1-Tyr-126). Fig.2 il- 
lustrates time-related release of IR-ANF during 
perfusion. IR-ANF was determined in each fifth 
2-ml sample. Its secretion was diminished with 
time but even after a 40-min perfusion, about 
50 pg/ml was found in the perfusate. After extrac- 
tion and RP-HPLC purification, a 30-min perfu- 
sion of 3 rat lungs yielded 44 ng of IR-ANF. 
Fig.3 reveals that the isolated IR-ANF was 
biologically active. It markedly inhibited 
forskolin-stimulated aldosterone secretion from 
rat zona glomerulosa cells in a manner comparable 
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Fig.1. Reverse-phase HPLC of extracts of rat lung 
homogenates (A) and perfusates (B). Arrows indicate 
the elution position of synthetic 28 amino acid ANF 
(Ser-99-Tyr-126) and 126 amino acid ANF prohormone 
(Asn-1-Tyr-126). 
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Fig.2. Time response of IR-ANF during a 40-min 
perfusion of isolated rat lung. 
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Fig.3. The effect of various concentrations of IR-ANF 
isolated for rat lung perfusates and synthetic ANF 
(Arg-lOl-Tyr-126) on forskolin (stippled column)- 
stimulated aldosterone secretion. The open column 
represents aldosterone under basal conditions. The bars 
represent he mean values f SE in two experiments of 4 
replicates each. * p < 0.001, ** p < 0.05. 
to the effect of synthetic ANF (Arg-lOl-Tyr-126). 
Aldosterone secretion was similarly suppressed by 
10e9 M synthetic ANF (Arg-lOl-Tyr-126) (51%) 
as well as by 2 x 10m9 M IR-ANF (59.9%) isolated 
from rat lung perfusates. No immunoreactive 
material was noted in corresponding fractions, of 
‘blank’ runs on RP-HPLC, which exerted no in- 
hibitory influence on aldosterone secretion. 
4. DISCUSSION 
Our results demonstrate the presence of multiple 
forms of ANF in rat lung extracts, including the 
126 amino acid ANF prohormone (Asn-l-Tyr- 
126) but only a low molecular mass C-terminal 
peptide, most probably a 28 amino acid peptide, is 
secreted. However, the structure of the ‘secreted 
IR-ANF has yet to be determined by amino acid 
analysis. Furthermore, the secreted IR-ANF was 
biologically active and its potency was similar to 
that of synthetic ANF (Arg-lOl-Tyr-126) [13]. 
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There are a few possible explanations for the 
presence of IR-ANF in the lungs, the most likely 
being that it is synthesized in this organ. This 
hypothesis is supported by a recent demonstration 
of ANF messenger RNA in rat lungs [14] and by 
detection of the 126 amino acid prohormone 
(fig. 1, immunoreactive peak (126 AA)) in rat lung 
homogenates. We have recently purified the 126 
amino acid rat ANF prohormone and have com- 
pared its RP-HPLC pattern with that of IR-ANF 
found in peak 126 AA [15]. So far, this form of 
ANF has not been noted in plasma, but only in car- 
diocyte granules. 
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Since ANF receptors have been discovered in the 
lungs through binding studies and autoradiog- 
raphy [ 161, plasma ANF could be bound to the 
lung tissue and released during perfusion. 
However, this is unlikely as perfusion was per- 
formed with Krebs buffer (pH 7.4), in which bin- 
ding between ligands and receptors is stable, and a 
considerable quantity of ANF is secreted (about 
14.3 ng/lung). 
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ANF is another peptide in a large number of 
peptide hormones and neurotransmitters that have 
been discovered in normal and pathological lung 
tissue [ 171. ANF may have a regulatory role in cer- 
tain pulmonary and cardiovascular disorders, such 
as pulmonary edema and pulmonary hypertension, 
during which higher ANF plasma levels have been 
found [18]. The contribution of pulmonary ANF 
to the circulating ANF pool and its place in 
physiology and lung diseases remain to be ex- 
plored. 
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